British biotech company Stabilitech BioPharma Ltd said on Wednesday that it has completed its COVID-19 Master Viral Seedstock, which it now intends to have manufactured and formulated into its patent protected capsule for oral vaccine delivery.

Following approval by regulatory authorities, the company will produce self-administered COVID-19 vaccine capsules that are inexpensive to produce, developed in weeks, thermally stable and can be posted direct to consumer.

The company obtained the COVID-19 genetic sequence as soon as it was available from China.

All novel vaccines must undergo clinical trials to gain regulatory approvals around the world.

Stabilitech is continuing to develop and license its technologies for partnerships and clinical trials.